PA NT COOPERATION TREAT

From	the	IN'	TFRI	TAV	10N	IAI	Bl.	JRE.	A١

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

):

Commissioner
US Department of Commerce

United States Patent and Trademark

Office, PCT

2011 South Clark Place Room

CP2/5C24

Arlington, VA 22202

ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year)

01 November 2000 (01.11.00)

International application No. PCT/US00/08519

International filing date (day/month/year) 30 March 2000 (30.03.00)

Applicant's or agent's file reference

OCR-1001

Priority date (day/month/year)

31 March 1999 (31.03.99)

Applicant

CAPPELLO, Michael et al

1.	The designated Office is hereby notified of its election made:
	X in the demand filed with the International Preliminary Examining Authority on:
	29 September 2000 (29.09.00)
	in a notice effecting later election filed with the International Bureau on:
2.	The election X was
2.	was not
	made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Authorized officer

Charlotte ENGER

Telephone No.: (41-22) 338.83.38

Facsimile No.: (41-22) 740.14.35





From the INTERNATIONAL SEARCHING AUTHORITY

To: MARY M. KRINSKY 79 TRUMBULL STREET

PCT

79 TRUMBULL STREET 10511-3708 1070 - Rec'd 25 SEP 2001	NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION (PCT Rule 44.1) Date of Mailing (day/month/year) 05 JUL 2000
Applicant's or agent's file reference	FOR FURTHER ACTION See paragraphs 1 and 4 below
OCR-1001 International application No.	International filing date (day/month/year) 30 MARCH 2000
PCT/US00/08519 Applicant YALE UNIVERSITY	
When? The time limit for filing such amen international search report; however, to the International Bureau of 34, chemin des Colon 1211 Geneva 20, Swi Facsimile No.: (41-22) For more detailed instructions, see the note:	itzerland 2) 740.14.35 is on the accompanying sheet. tional search report will be established and that the declaration under
3. With regard to the protest against payment of the protest together with the decision the	of (an) additional fee(s) under Rule 40.2, the applicant is notified that: reon has been transmitted to the International Bureau together with the frost the protest and the decision thereon to the designated Offices. rotest; the applicant will be notified as soon as a decision is made.
priority claim, must reach the International Bure priority claim, must reach the International Bure completion of the technical preparations for interview of the priority date, a demand within 19 months from the priority date, a demand the technique the entry into the national plants.	nternational application will be provided in the international application, or of the cation, a notice of withdrawal of the international application, or of the cau as provided in rules 90 bis 1 and 90 bis 3, respectively, before the mational publication. If for international preliminary examination must be filed if the applicant hase until 30 months from the priority date (in some Offices even later). Int must perform the prescribed acts for entry into the national phase before the demand or in a later election within 19 months from the priority the demand or in a later election within 19 months from the priority.
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer HOLLY SCHNIZER Telephone No. (703) 308-0196

Facsimile No. (703) 305-3230



PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference OCR-1001	FOR FURTHER ACTION	see Notification of Transmittal of International Search Repo- (Form PCT/ISA/220) as well as, where applicable, item							
International application No.	International filing date	c (day/month/year)	(Earliest) Priority Date (day/month/year)						
PCT/US00/08519	30 MARCH 2000		30 MARCH 1999						
Applicant YALE UNIVERSITY									
according to Article 18. A copy is being	ng transmitted to the Intern	ational Bureau.	ority and is transmitted to the applicant						
This international search report consist X It is also accompanied by a			eport.						
Basis of the report With regard to the language, if	ne international seamh was o	parried out on the basi	is of the international application in the						
language in which it was filed	, unless otherwise indicated	under this item.							
the international search wa Authority (Rule 23.1(b)).	s carried out on the basis	of a translation of th	ne international application furnished to this						
b. With regard to any nucleotide was carried out on the basis of	-	ce disclosed in the in	ternational application, the international search						
X contained in the internation	al application in written fo	rm.							
X filed together with the inter	national application in con	nputer readable form							
furnished subsequently to t	his Authority in written fo	rm.							
furnished subsequently to	his Authority in computer	readable form.							
1 1 1		sequence listing does	not go beyond the disclosure in the						
international application as the statement that the inform furnished.		readable form is iden	ntical to the written sequence listing has been						
2. Certain claims were four	d unsearchable (See Box	I).							
3. Unity of invention is lack	ting (See Box II).								
4. With regard to the title,									
X the text is approved as sub	mitted by the applicant.								
the text has been establish	ed by this Authority to rea	d as follows:							
			·						
5. With regard to the abstract,									
the text is approved as sub	mitted by the applicant.		į						
Box III. The applicant may	the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.								
6. The figure of the drawings to be published with the abstract is Figure No. 1									
X as suggested by the applic	ant.		None of the figures.						
because the applicant faile	d to suggest a figure.								
because this figure better of	haracterizes the invention.								

HALE TO THE STATE OF THE STATE			
CLASSIFICATION OF SUBJECT MATTER			
	مراجع المستندات	LIPC	
PC(7) :C07K 1/00, 14/00, Refressor JS CL :514/2, 822; 530/350 cording to International Patent Classification (IPC) or to both no	ational classification and	11.0	
cording to International Facility			
FIELDS SEARCHED nimum documentation searched (classification system followed	by classification symbo	is)	
nimum documentation searched (Classification)			
J.S.: 514/2, 822; 530/350 Ocumentation searched other than minimum documentation to the		-to are included in	the fields searched
to the minimum documentation to the	extent that such docume	its are more	
ocumentation searched other than influence			
	and w	here practicable, s	earch terms used)
lectronic data base consulted during the international search (na	ame of data base and, w	nere p	
lectronic data base consumer 5			
Please See Extra Sheet.			
		_	
C. DOCUMENTS CONSIDERED TO BE RELEVANT		2900000	Relevant to claim No.
Category Citation of document, with indication, where a	ppropriate, of the relevar	it passages	
Category* Citation of document, with inter-	NOTTINGHAI	M) 11 May	12 and 16-19
Y WO 95/12615 A1 (UNIVERSITY C	JE NOTIMOTHE	11, claim 2,	
1,005 (11/05/1993), See Chino 30	ent, especiant P	·	1-20
12 claim /, and Figure 4.		1	. a. 44 and 16-19
	octatic strategies o	f the human	12, 14, and 16-19
FURMIDGE et al. The anti-haemo hookworm Necator americanus. Para	sitology, 1995, Vo	1. 112, pages	1.00
hookworm Necator americanus. Fala	and page 86.		1-20
hookworm Necator americanas: 1 and 81-87, especially page 84, figure 3,	une pag		
A			
Δ			
			·
	See D	atent family annex	ζ.
Further documents are listed in the continuation of I	BUX U		t culture data or priority
Land de la companie	date and	not in conflict with the iple or theory underlying	e international filing date of prisons application but cited to understanding the invention
Special categories of cited documents: document defining the general state of the art which is not consider the constitution of the const	idered the princi	ible of alcord	t i marting cannot b
'A' document defining the general to be of particular relevance	date considere	ed novel or cannot be co	ce; the claimed invention consistency considered to involve an inventive sterence
earlier document published on or after the international trans-	when the	e document is discon-	e :
document which may throw doubts on priority document which may be priority document which may be presented by the priority document which may be priority document.		nt of particular relevant red to involve an inv	entive step when the document ster such documents.
cited to establish are	COLLEGE	ed with one or more other byious to a person skill	entive step when the documents ter such documents, such combination and in the art
document referring to an oral disclosure, use, extracted		ent member of the same	patent family
means	ter than "A" docume	California and in the	al search report
the priority date claimed	Date of mailing	of the internation	2000
Date of the actual completion of the international search		05 JUL	
14 JUNE 2000			
	Authorized off	41	· OA
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks	HOLLY S	CHNIZER	ady
	Telephone No		96
Washington, D.C. 20231	I elephone No	·	

B. FIELDS SEARCHED Electronic data bases consulted (Name of data base and where practicable terms used):					
STN (MEDLINE, BIOSIS, CAPLUS); EAST; search terms: GPIIb/IIIa, GPIa/IIa, fibrinogen, collagen, ancyclostoma duodenale, ancyclostoma ceylanicum, necator americus, ancyclostoma canimum, hookworm, platelet inhibition, epinephrine, thrombin, ADP, apyrase.					
epinephrine, infomolii, ADF, apyrase.					

PTOPET Rec'd 25 SEP 01 PATENT COOPERATION TREATY

From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY						
To: MARY M. KRINSKY 79 TRUMBULL STREET NEW HAVEN, CT 06511-3708	PCT WRITTEN OPINION					
	(PCT Rule 66)					
(da	ate of Mailing 20 AUG 2001					
Applicant's or agent's file reference RI OCR-1001	EPLY DUE within 1 months/days from the above date of mailing					
International application No. International filing date (da)	/month/year) Priority date (day/month/year)					
20.14 1 2000 (20.02 2000	31 March 1999 (31.03.1999)					
PCT/US00/08519 30 March 2000 (30.03.2000 International Patent Classification (IPC) or both national classification						
1						
IPC(7): C07K 1/00, 14/00; A61K 38/00 and US C1.: 514/2, 822; 530. Applicant						
YALE UNIVERSITY						
C. (C) desum by this	International Preliminary Examining Authority.					
1. This written opinion is the first (first, etc.) drawn by this						
2. This opinion contains indications relating to the following	items:					
I Basis of the opinion						
II Priority						
III Non-establishment of opinion with regard to no	ovelty, inventive step and industrial applicability					
IV Lack of unity of invention						
V Reasoned statement under Rule 66.2 (a)(ii) wire citations and explanations supporting such state	th regard to novelty, inventive step or industrial applicability;					
VI Certain documents cited						
VII Certain defects in the international application						
VIII Certain observations on the international appli						
3. The applicant is hereby invited to reply to this opinion.						
When? See the time limit indicated above. The chis Authority to grant an extension. See	upplicant may, before the expiration of that time limit, request rule 66.2(d).					
How? By submitting a written reply, accompani For the form and the language of the ame	ed, where appropriate, by amendments, according to Rule 66.3.					
Also For an additional opportunity to submit amendments, see Rule 66.4. For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis. For an informal communication with the examiner, see Rule 66.6						
If no reply is filed, the international preliminary examin	nation report will be established on the basis of this opinion.					
 The final date by which the international preliminary examination report must be established according to Rul 						
No. and mailing addrage of the IDEA/IJS	Authorized officer TERRY J. DEY					
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks	Stephen Tu PARALEGAL SPECIALIST					
Box PCT Washington, D.C. 20231	Telephone No. 703-3 JECHNOLOGY CENTER 1600					
Facsimile No. (703)305-3230						

International application No.

WRITTEN OPINION

PCT/US00/08519

I.	Bas	is of the opinion					
1.	With	regard to the elements of the international application:*					
	\boxtimes	the international application as originally filed					
	\boxtimes	the description:					
		pages 1-25, as originally filed					
		pages NONE , filed with the demand					
		pages NONE , filed with the letter of					
	\boxtimes	the claims:					
		pages 26 and 27, as originally filed					
		pages NONE , as amended (together with any statement) under Article 19					
		pages NONE , filed with the demand					
	_	pages NONE , filed with the letter of					
	\boxtimes	the drawings:					
		pages 1-5 , as originally filed					
		pages NONE , filed with the demand pages NONE , filed with the letter of					
	_	pages NUNE, filed with the letter of					
	\boxtimes	the sequence listing part of the description:					
		pages 1-2 , as originally filed					
		pages NONE , filed with the demand					
		pages NONE , filed with the letter of					
	langı	regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item. e elements were available or furnished to this Authority in the following language which is: the language of a translation furnished for the purposes of international search (under Rule23.1(b)).					
		the language of publication of the international application (under Rule 48.3(b)).					
		the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).					
3.	With opini	regard to any nucleotide and/or amino acid sequence disclosed in the international application, the written on was drawn on the basis of the sequence listing:					
	\boxtimes	contained in the international application in printed form.					
	\boxtimes	filed together with the international application in computer readable form.					
		furnished subsequently to this Authority in written form.					
	$\overline{}$	furnished subsequently to this Authority in computer readable form.					
		The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.					
		The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.					
4.		The amendments have resulted in the cancellation of:					
		the description, pages NONE					
		the claims, Nos. NONE					
,	_	the drawings, sheets /fig NONE					
5. [This opinion has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).					
* R this	Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in his opinion as "originally filed."						
0.000	DCT	/IDEA/409 (Pay I) (July 1009)					



International application	No.
International application	•
PCT/US00/08519	
PC11/0300/00312	

WRITTEN OPINION asoned statement under Rule 66.2(a)(ii)		l	
			industrial applicability;
	with regard	to novelty, inventiv	ve step or industrial appara
econed statement under Rule 66.2(a)(ii)	Will regard		
asoned statement under Rule 66.2(a)(a) ations and explanations supporting such	Statement		
			YES
ATEMENT	ot dans	L-20	NONO
Novelty (N)	Claims	NONE	NO
Noverty (14)	Claims	NONE	YES
			NO
tue Stan (IS)	Claims	1-11, 13, 13, 20	NO
Inventive Step (IS)	Claims	12, 14, 10-19	
			YES
e stiller (IA)	Claims	1-20	NO
Industrial Applicability (IA)	Claims	NONE	
CITATIONS AND EXPLANATIONS ms 1-20 meet the criteria for novelty under Pc 2 or methods of treatment to inhibit platelet from 1-11, 13, 15, and 20 meet the criteria for ypeptide of SEQ ID NO:2 or methods of treatments 12, 14, and 16-19 lack an inventive step view of FURMIDGE et al., (Parasitology (19 cretory-secretory (ES) products of Necator and is not teach or suggest mechanism by which thich the ES products of N. Americanus inhibit in the interaction of fibrinogen with platelet a claims 1-20 meet the criteria for industrial appoints. NEW CITATIONS	novelty under ment to inhibit under PCT Arti 95) 112: 81-87, nericanus, partihese proteins in platelet aggreg IlbB3, which A licability as def	PCT Article 33(3), being platelet function utilizatele 33(3) as being obtoned in PRITCHARD et al. cularly as an inhibitor thibit platelet aggregatation. Specifically, the applicant has referred to the policy of the property of the propert	wing the polypeptide, as set forth in these claring the polypeptide, as set forth in these claring the polypeptide, as set forth in these claring the polypeptide in teaches the pharmaceutical use of derivative of platelet aggregation. However the refere tion. FURMIDGE et al. teaches mechanism he references indicates that the proteins interfere to as GPIIb/IIIa.

Form PCT/IPEA/408 (Box V) (July 1998)



International application No. PCT/US00/08519

WRITTEN OPINION	
Supplemental Box (To be used when the space in any of the preceding boxes is not sufficient) TIME LIMIT: The time limit set for response to a Written Opinion may not be extended. 37 (expiration of the time limit set in the Written Opinion will not be considered in	CFR 1.484(d). Any response received after the preparing the International Preliminary Examination
The time limit set in the Written Opinion will not be expiration of the time limit set in the Written Opinion will not be expiration.	

PATENT COOPERATION TREATY

REC'D	15	MAR	2002
			DCT

PCT MISO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

	(PCT Article 36 and 1	,	
- Coronce		See Notification	on of Transmittal of International Examination Report (Form PCT/IPEA/416)
pplicant's or agent's file reference	FOR FURTHER ACTION		Priority date (day/month/year)
OCR-1001 mernational application No.	International filing date (day/mo.		31 March 1999 (31.03.1999)
PCT/US00/08519 International Patent Classification (IPC)	30 March 2000 (30.03.2000) or national classification and IPC		
International Patent Classification (11C) IPC(7): C07K 1/00, 14/00; A61K 38/C	x) and US Cl.: 514/2, 822; 530/350)	
IPC(7): C07K 1/00, 14/00; A61K 36/C			
VALE UNIVERSITY			by this International Preliminary
This international preli	ninary examination report has been distransmitted to the applicant	seen prepared at according to	by this International Preliminary Article 36.
Examining Additions	3 include	ing this cover	sheet.
2. This REPORT consists	of a total of	ie sheets of	the description, claims and/or drawings /or sheets containing rectifications made Administrative Instructions under the PCT).
This report is also	accompanied by ANNEXES.	this report and	the description, claims and/or diameters of the description, claims and/or sheets containing rectifications made Administrative Instructions under the PCT).
which have been before this Author	ority (see Rule 70.16 and Section	on 607 of the 1	/or sheets containing rectifications made /or sheets /or shee
ana consis	t of a total of <u>U</u> sheets.		
2 This report contains	indications relating to the follow	wing items:	,
N Pagis of the			
1 Basis of a	·	day in	ventive step and industrial applicability
II Non-esta	blishment of report with regard	to novelly, in	ventive step and industrial applicability
Lack of unity of invention			
Reasoned statement under Article 35(2) with regard to the V Reasoned statement under Article 35(2) with regard to the V applicability; citations and explanations supporting such statement			
☐ Germin	documents cited		
VII Certain	defects in the international app	nication	
VIII Certair	observations on the internation		
			ompletion of this report
Date of submission of the o		26 Februa	ry 2002 (26.02.2002)
29 September 2000 (29,09.20	000)	Author	some Budgers &
Name and mailing address of Commissioner of Paent	The IPEA/OS S and Trademarks		n Kfun
Box PCT - Wishington, D.C. 202 - 205, 305, 323	31	Telephon	ne No. (703) 308-0196
Facsimile No. (703)305-323 Form PCT/IPEA: 409 (cover	sheet)(July 1998)		
Louis			


INTERNATIONAL PRELIMINARY EXAMINATION REPORT

8

nternational	application	No	
illerizationa	application	110.	

PCT/US00/08519

1.	Basis of the report
١.	With regard to the elements of the international application:*
	the international application as originally filed.
	the description:
	pages 1-25 as originally filed pages NONE filed with the demand
	pages NONE, filed with the letter of
	the claims:
	pages 26 and 27 as originally filed
	pages NONE, as amended (together with any statement) under Article 19
	pages NONE , filed with the demand pages NONE , filed with the letter of
	the drawings: pages 1-5, as originally filed
	pages NONE filed with the demand
	pages NONE, filed with the letter of
	the sequence listing part of the description:
	pages 1-2, as originally filed
	pages NONE, filed with the demand, filed with the letter of,
,	With regard to the language, all the elements marked above were available or furnished to this Authority in the
	language in which the international application was filed, unless otherwise indicated under this item.
	These elements were available or furnished to this Authority in the following language which is:
	the language of a translation furnished for the purposes of international search (under Rule23.1(b)).
	the language of publication of the international application (under Rule 48.3(b)).
	the language of the translation furnished for the purposes of international preliminary examination(under Rules
	55.2 arxl/or 55.3).
3.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:
	contained in the international application in printed form.
	filed together with the international application in computer readable form.
	furnished subsequently to this Authority in written form.
	furnished subsequently to this Authority in computer readable form.
	The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
	The statement that the information recorded in computer readable form is identical to the written sequence listing
	has been furnished.
4.	The amendments have resulted in the cancellation of:
	the description, pages NONE
	the claims, Nos. NONE
	the drawings, sheets/fig NONE
5.	This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**
th	Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in is report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17). * Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

	INTERNATIONAL		industrial applicability:
V.	Reasoned statement under Rule 66.2(a)(ii) vicitations and explanations supporting such	vith regard to novelty statement	, inventive step or industrial application,
	STATEMENT		YES
	Novelty (N)	Claims 1-20 Claims NONE	NO
	Inventive Step (IS)	Claims 1-11, 13, 13 Claims 12, 14, 16-	
	Industrial Applicability (IA)	Claims 1-20 Claims NONE	YES NO

Claims 1-20 meet the criteria for novelty under PCT Article 33(2), because the prior art does not disclose the polypeptide of SEQ ID NO:2 or methods of treatment to inhibit platelet function utilizing the polypeptide, as claimed by Applicants.

Claims 1-11, 13, 15 and 20 meet the criteria for novelty under PCT Article 33(3), because the prior art does not teach the polypeptide of SEQ ID NO:2 or methods of treatment to inhibit platelet function utilizing the polypeptide, as set forth in these claims.

Claims 12, 14 and 16-19 lack an inventive step under PCT Article 33(3) as being obvious over PRITCHARD et al. (WO 95/12615) in view of FURMIDGE et al. (Parasitology (1995) 112:81-87). PRITCHARD et al. teach the pharmaceutical use of derivatives of excretory-secretory(ES) products of Necator americanus, particularly as an inhibitor of platelet aggregation. However, the reference does not teach or suggest mechanism by which these proteins inhibit platelet aggregation. FURMIDGE et al. teach mechanisms by which the ES products of N. americanus inhibit platelet aggregation. Specifically, the references indicate that the proteins interfere with the interaction of fibrinogen with platelet allbB3, which Applicant has referred to as GPIIb/IIIa.

Claims 1-20 meet the criteria for industrial applicability as defined by PCT Article 33(4).

Form PCT/IPEA/409 (Box V) (July 1998)



100 C A



INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/08519

IPC(7) US CL	ASSIFICATION OF SUBJECT MATTER :C07K 1/00, 14/00; A61K 38/00 :514/2, 822; 530/350 to International Patent Classification (IPC) or to bo	th national classification and IPC	
1	LDS SEARCHED		
Minimum	documentation searched (classification system follow	wed by classification symbols)	
U.S. :			
Documents	ation searched other than minimum documentation to	the extent that such documents are include	d in the fields searched
Electronic	data base consulted during the international search (name of data base and where practicable	
	ce Extra Sheet.	of com one one, where precucable	e, search terms used)
	CUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where a		Relevant to claim No.
Y 	WO 95/12615 A1 (UNIVERSITY (1995), see entire document	OF NOTTINGHAM) 11 May	12 and 16-19
Α	p. 12, claim 7, and Figure 4.	,	1-20
Y	FURMIDGE et al. The anti-haemos hookworm <i>Necator americanus</i> . Paras	static strategies of the human	12, 14, and 16-19
	81-87, especially page 84, figure 3, a	nd page 86	1-20
Α	, 1 , 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1	ne puge co.	1-20
	•		
Furth	er documents are listed in the continuation of Box (See patent family annex.	
=	ecial categories of cited documents:	"T" later document published after the inte date and not in conflict with the appli	rnational filing date or priority
	nument defining the general state of the art which is not considered be of particular relevance	the principle of theory underlying the	invention
	lier document published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be consider	claimed invention cannot be
cite	tument which may throw doubts on priority claim(s) or which is to establish the publication date of another citation or other	when the document is taken alone	
	cial reason (as specified) nument referring to an oral disclosure, use, exhibition or other	"Y" document of particular relevance; the considered to involve an inventive	sten when the document is
mee	ans	combined with one or more other such being obvious to a person skilled in the	documents, such combination
the	nument published prior to the international filing date but later than priority date claimed	*& document member of the same patent	
Date of the actual completion of the international search Date		Date of mailing of the international sear	rch report
14 JUNE 2		05 JUL 20	000
Commission	nailing address of the ISA/US are of Patents and Trademarks	Authorized officer	
Box PCT Washington,	, D.C. 20231	HOLLY SCHNIZER	
acsimile No	o. (703) 305-3230	Telephone No. (703) 308-0196	

Form PCT/ISA/210 (second sheet) (July 1998)*





INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/08519

B. FIELDS SEARCHED Electronic data bases consulted (Name of data base and where practicable terms used):			
STN (MEDLINE, BIOSIS, CAPLUS); EAST; search terms: GPIIb/IIIa, GPIa/IIa, fibrinogen, collagen, ancyclostoma duodenale, ancyclostoma ceylanicum, necator americus, ancyclostoma canimum, hookworm, platelet inhibition, epinephrine, thrombin, ADP, apyrase.			
·			